Search

NVG-111: a phase 1/2 trial of NVG-111 in relapsed or refractory chronic lymphocytic leukaemia, small lymphocytic lymphoma and mantle cell lymphoma

Trial

… back (relapsed) or not responded to previous treatment (refractory). This is a phase 1 (early phase) trial . Little … large B cell lymphoma (DLBCL which has not responded to (refractory), or has come back after (relapsed) treatment may … A phase 1 trial testing NVG-111 in people with relapsed or refractory chronic lymphocytic leukaemia (CLL), small …

Lenalidomide recommended for relapsed or refractory follicular lymphoma

Standard post

… lymphoma that has come back (relapsed) or not responded (refractory) to previous treatment. Follicular lymphoma is the … A phase 3 clinical trial in people with relapsed or refractory low-grade lymphoma found that lymphoma did not … Clinical evidence suggests that people with relapsed or refractory follicular lymphoma who are treated with …

Encouraging trial results for relapsed or refractory DLBCL

Standard post

… lymphoma ( DLBCL ) that has relapsed (come back) or is refractory (didn’t respond) to previous treatment. … lenalidomide and gemcitabine-based regimens in relapsed or refractory DLBCL or other lymphomas.  To find out more about … Haematology. … Encouraging trial results for relapsed or refractory DLBCL …

Promising results for acalabrutinib in people with relapsed or refractory CLL

Standard post

… results for acalabrutinib in people with relapsed or refractory chronic lymphocytic leukaemia (CLL). Acalabrutinib … (CLL) that had come back (relapsed) or had not responded (refractory) to previous treatment. The trial found that … improves the length of time people with relapsed or refractory CLL live without disease progression compared with …